To test the epigenetic responsiveness to DNA methylation of CLDN10, we treated ccRCC cell lines with a pharmacological inhibitor of DNMTs (5-Aza-2’-deoxycytidine, Aza), that hinders methylation of DNA across the epigenome. The gene discussed is CLDN10; the disease is nonpapillary renal cell carcinoma.